Worldwide sales of weight-loss and diabetes jab Mounjaro have doubled this yearWorldwide sales of weight loss and diabetes jab Mounjaro have doubled this year as demand continues to boom, drugmaker Eli Lilly has revealed. The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales. Mounjaro sales totalled 18.6 billion dollars (£13.8 billion) in the first six months of the year – up by 106% compared with the same period in 2025. Zepbound sales also leaped by 60% year-on-year to 9.1 billion dollars (£6.8 billion). It is now expecting revenues to total between 85 and 87 billion dollars (£63 billion to £65 billion) up from a previously guided range of 82 to 85 billion dollars (£61 billion to £63 billion).